跳至主要内容
临床试验/EUCTR2022-002310-16-BE
EUCTR2022-002310-16-BE进行中(未招募)1 期

Endometrial gene expression profiles during ovarian stimulation with recombinanthuman FSH with or without the addition of recombinant human LH in genuine poor responders. - ELIPSe trial (Endometrial gene expression with LH addition In Poor ovarian responderS)

Z Brussel0 个研究点目标入组 36 人开始时间: 2022年12月6日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • Subfertility/infertility
  • Age =35 = 40 years
  • Undergoing ICSI
  • BMI = 19 and = 30 kg/m²
  • AMH <1.2 ng/mL
  • Previous conventional ovarian stimulation (OS) with < 4 metaphase II (MII) oocytes
  • Regular menstrual cycle (26-35 days)
  • Non-smokers
  • Acceptance to do two consecutive ovarian stimulation cycles (between 1-6 months)
  • Signed informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 36
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Endometriosis > rAFS grade II
  • Testicular sperm extraction
  • Recurrent miscarriage (>2 previous miscarriages)
  • Ovarian stimulation for pre-implantation genetic testing (PGT-A/M)
  • Medical/social oocyte vitrification
  • In vitro maturation (IVM)
  • Untreated auto-immune, endocrine, or metabolic disorders
  • Asherman’s syndrome
  • Medical history of coagulopathies
  • Severe OHSS in a previous treatment cycle

研究者

发起方
Z Brussel

相似试验